Manufacturers announce positive data for deucravacitinib for moderate to severe plaque psoriasis

In the POETYK PSO-2 phase III study, this a once daily, oral, selective tyrosine kinase 2 (TYK2) inhibitor that inhibits IL-12, IL-23 and type 1 interferon pathways was found to be superior to both placebo and apremilast at achieving PASI 75 response at 16 weeks.

Source:

Biospace Inc.